Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Dumortier

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Bulletin Du Cancer|December 1, 1993
[In memoriam Michel Clavel]T Philip, A Dumortier
Bulletin Du Cancer|January 22, 1998
[Efficacy of massage and mobilization of the upper limb after surgical treatment of breast cancer]B Le Vu, A Dumortier, M V Guillaume, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 1, 1994
A phase I antiemetic study of MDL 73,147EF, a novel 5-hydroxytryptamine antagonist in cancer patients receiving emetogenic chemotherapyY Merrouche, G Catimel, P Rebattu, et al.
Bulletin Du Cancer|October 20, 2000
[Huriet law: application in a regional cancer centre (Centre Léon-Bérard, Lyon)]G Chvetzoff, I Ray-Coquard, A Dumortier, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1995
Phase I study of RP 49532A, a new protein-synthesis inhibitor, in patients with advanced refractory solid tumorsG Catimel, R Coquard, J P Guastalla, et al.
Journal of Affective Disorders|December 1, 1984
Double-blind clinical study comparing alprazolam and doxepin in primary unipolar depressionM Ansseau, C Ansoms, G Beckers, et al.
Anti-Cancer Drugs|February 1, 1995
Phase I and pharmacokinetic study of a novel mitomycin C analog KW-2149L Dirix, G Catimel, I Koier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 1995
Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumorsG Catimel, G G Chabot, J P Guastalla, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 13, 2000
Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trialsT Bachelot, I Ray-Coquard, G Catimel, et al.
Seminars in Oncology|February 1, 1997
Phase I studies of combined paclitaxel/epirubicin and paclitaxel/epirubicin/cyclophosphamide in patients with metastatic offast cancer: the French experienceG Catimel, M Spielmann, V Dieras, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Bulletin Du Cancer|December 1, 1993
[In memoriam Michel Clavel]T Philip, A Dumortier
Bulletin Du Cancer|January 22, 1998
[Efficacy of massage and mobilization of the upper limb after surgical treatment of breast cancer]B Le Vu, A Dumortier, M V Guillaume, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 1, 1994
A phase I antiemetic study of MDL 73,147EF, a novel 5-hydroxytryptamine antagonist in cancer patients receiving emetogenic chemotherapyY Merrouche, G Catimel, P Rebattu, et al.
Bulletin Du Cancer|October 20, 2000
[Huriet law: application in a regional cancer centre (Centre Léon-Bérard, Lyon)]G Chvetzoff, I Ray-Coquard, A Dumortier, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1995
Phase I study of RP 49532A, a new protein-synthesis inhibitor, in patients with advanced refractory solid tumorsG Catimel, R Coquard, J P Guastalla, et al.
Journal of Affective Disorders|December 1, 1984
Double-blind clinical study comparing alprazolam and doxepin in primary unipolar depressionM Ansseau, C Ansoms, G Beckers, et al.
Anti-Cancer Drugs|February 1, 1995
Phase I and pharmacokinetic study of a novel mitomycin C analog KW-2149L Dirix, G Catimel, I Koier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 1995
Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumorsG Catimel, G G Chabot, J P Guastalla, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 13, 2000
Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trialsT Bachelot, I Ray-Coquard, G Catimel, et al.
Seminars in Oncology|February 1, 1997
Phase I studies of combined paclitaxel/epirubicin and paclitaxel/epirubicin/cyclophosphamide in patients with metastatic offast cancer: the French experienceG Catimel, M Spielmann, V Dieras, et al.
Pageof 2